Ribose-5-phosphate isomerase deficiency
Ribose-5-phosphate isomerase deficiency is a human disorder caused by mutations in the pentose phosphate pathway enzyme ribose-5-phosphate isomerase. With only three diagnosed patients over a 27-year period, RPI deficiency is currently the rarest disease in the world.[1]
Mechanism[edit | edit source]
In the search for an explanation for this rarity, it has been found that the patient has a seldom-seen allelic combination.[1] One allele is a non-functional null allele, while the other encodes for a partially active enzyme. Furthermore, the partially functional allele has expression deficits that depend on the cell type in which it is expressed. Therefore, some of the patient's cells have a considerable amount of Rpi activity, whereas others do not.
The molecular cause of the pathology is not fully understood. One hypothesis is that ribose-5-phosphate may lack for RNA synthesis; another possibility is that the accumulation of D-ribitol and D-arabitol may be toxic.
Diagnosis[edit | edit source]
Symptoms include optic atrophy, nystagmus, cerebellar ataxia, seizures, spasticity, psychomotor retardation, leukoencephalopathy and global developmental delay.[2]
Treatment[edit | edit source]
There is no current treatment as well as prognosis for ribose-5-phosphate isomerase deficiency.
History[edit | edit source]
In 1999 van der Knaap and colleagues [3] [4] described a 14-year-old boy with developmental delay, insidious psychomotor regression, epilepsy, leukoencephalopathy and abnormal polyol metabolism. Later, Naik and colleagues [5] reported a second case, an 18-year-old man with seizures, psychomotor regression and diffuse white matter abnormality. A third case was reported in 2018 by Sklower Brooks and colleagues, a child with neonatal onset leukoencephalopathy and psychomotor delays.[6]
References[edit | edit source]
- ↑ 1.0 1.1
- ↑ "Ribose 5-Phosphate Isomerase Deficiency disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials". www.malacards.org. Retrieved 2018-03-05.
- ↑ van der Knapp MS, Wevers RA, Struys EA, et al. Leukoencephalopathy associated with a disturbance in the metabolism of polyols.Ann Neurol. 1999;46(6):925-928.
- ↑ Huck, J. H. J.; Verhoeven, N. M.; Struys, E. A.; Salomons, G. S.; Jakobs, C.; Van Der Knaap, M. S. (2004). "Ribose-5-Phosphate Isomerase Deficiency: New Inborn Error in the Pentose Phosphate Pathway Associated with a Slowly Progressive Leukoencephalopathy". The American Journal of Human Genetics 74 (4): 745–751. PMC 1181951. PMID 14988808. doi:10.1086/383204.
- ↑ Naik N, Shah A, Wamelink MMC, van der Knaap MS, Hingwala D. Rare case of ribose 5 phosphate isomerase deficiency with slowly progressive leukoencephalopathy. Neurology. 2017;89:1-2.
- ↑ Sklower Brooks S, Anderson S, Bhise V, Botti C. Further Delineation of Ribose-5-phosphate Isomerase Deficiency: Report of a Third Case, Journal of Child Neurology: First Published August 10, 2018 Journal of Child Neurology. https://doi.org/10.1177/0883073818789316
External links[edit | edit source]
| Classification | |
|---|---|
| External resources |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
